Similar articles

• Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.

  Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Osaki A, et al. Am J Surg. 1992 Oct;164(4):323-6. doi: 10.1016/s0002-9610(05)80897-9. Am J Surg. 1992. PMID: 1357997
• Significance of immunohistochemical c-erbB-2 product localization pattern for prognosis of primary human breast cancer.

  Zschiesche W, Schönborn I, Minguillon C, Spitzer E. Zschiesche W, et al. Cancer Lett. 1994 Jun 15;81(1):89-94. doi: 10.1016/0304-3835(94)90169-4. Cancer Lett. 1994. PMID: 7912648
• C-erbB-2 overexpression in primary breast cancer: independent prognostic factor in patients at high risk.

  Schönborn I, Zschiesche W, Spitzer E, Minguillon C, Möhner M, Ebeling K, Grosse R. Schönborn I, et al. Breast Cancer Res Treat. 1994;29(3):287-95. doi: 10.1007/BF00666483. Breast Cancer Res Treat. 1994. PMID: 7914107
• The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer.

  Gullick WJ, Srinivasan R. Gullick WJ, et al. Breast Cancer Res Treat. 1998;52(1-3):43-53. doi: 10.1023/a:1006107016969. Breast Cancer Res Treat. 1998. PMID: 10066071 Review.
• Growth factors. Clinical implications in breast cancer.

  Klijn JG, Berns PM, Bontenbal M, Foekens JA. Klijn JG, et al. Ann N Y Acad Sci. 1993 Nov 30;698:85-101. doi: 10.1111/j.1749-6632.1993.tb17193.x. Ann N Y Acad Sci. 1993. PMID: 8279785 Review. No abstract available.